HK1176617A1 - -{ }- -氟- -{ 甲氨基 甲基 苯基}- -四氫- -氮雜並 吲哚- -酮的鹽和多晶型物 - Google Patents

-{ }- -氟- -{ 甲氨基 甲基 苯基}- -四氫- -氮雜並 吲哚- -酮的鹽和多晶型物

Info

Publication number
HK1176617A1
HK1176617A1 HK13103915.1A HK13103915A HK1176617A1 HK 1176617 A1 HK1176617 A1 HK 1176617A1 HK 13103915 A HK13103915 A HK 13103915A HK 1176617 A1 HK1176617 A1 HK 1176617A1
Authority
HK
Hong Kong
Prior art keywords
azepino
polymorphs
indol
methylamino
tetrahydro
Prior art date
Application number
HK13103915.1A
Other languages
English (en)
Chinese (zh)
Inventor
派翠西亞．安．巴斯福德
安東尼．邁克爾．沃佩塔
亞當．吉爾莫
馬修．卡梅隆．琼斯
埃萊夫塞里奧斯．庫庫略斯
休曼．盧特拉
羅伯特．沃爾頓
Original Assignee
輝瑞大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43859823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1176617(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 輝瑞大藥廠 filed Critical 輝瑞大藥廠
Publication of HK1176617A1 publication Critical patent/HK1176617A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
HK13103915.1A 2010-02-12 2013-03-28 -{ }- -氟- -{ 甲氨基 甲基 苯基}- -四氫- -氮雜並 吲哚- -酮的鹽和多晶型物 HK1176617A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30427710P 2010-02-12 2010-02-12
PCT/IB2011/050571 WO2011098971A1 (en) 2010-02-12 2011-02-10 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Publications (1)

Publication Number Publication Date
HK1176617A1 true HK1176617A1 (zh) 2013-08-02

Family

ID=43859823

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13103915.1A HK1176617A1 (zh) 2010-02-12 2013-03-28 -{ }- -氟- -{ 甲氨基 甲基 苯基}- -四氫- -氮雜並 吲哚- -酮的鹽和多晶型物

Country Status (30)

Country Link
US (5) US8754072B2 (no)
EP (4) EP3150610B1 (no)
JP (6) JP5745283B2 (no)
KR (2) KR102108226B1 (no)
CN (2) CN102884066B (no)
AR (2) AR080164A1 (no)
AU (1) AU2011213944B2 (no)
CA (2) CA2787881C (no)
CY (3) CY1118319T1 (no)
DK (2) DK2534153T3 (no)
ES (2) ES2607806T3 (no)
HK (1) HK1176617A1 (no)
HR (2) HRP20161742T1 (no)
HU (3) HUE047248T2 (no)
IL (1) IL220921B (no)
LT (3) LT3150610T (no)
LU (1) LUC00093I2 (no)
MX (1) MX343383B (no)
NL (1) NL300958I2 (no)
NO (1) NO2018039I1 (no)
NZ (1) NZ601445A (no)
PL (2) PL3150610T3 (no)
PT (2) PT2534153T (no)
RS (2) RS59494B1 (no)
RU (1) RU2570198C2 (no)
SG (2) SG10201406805RA (no)
SI (2) SI2534153T1 (no)
SM (1) SMT201600462B (no)
TW (1) TWI545123B (no)
WO (1) WO2011098971A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150610B1 (en) * 2010-02-12 2019-07-31 Pfizer Inc Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
TW201516636A (zh) * 2013-10-22 2015-05-01 Hon Hai Prec Ind Co Ltd 電子裝置及其供電方法
US9987285B2 (en) * 2014-08-22 2018-06-05 Clovis Oncology, Inc. High dosage strength tablets of rucaparib
BR112018073667A2 (pt) * 2016-05-16 2019-03-12 Pulmagen Therapeutics (Asthma) Limited cristal de derivado de quinolina
DE102016218772A1 (de) * 2016-09-28 2018-03-29 Bruker Biospin Gmbh Verbesserte Temperierung eines NMR-MAS-Rotors
KR20190110579A (ko) 2017-01-24 2019-09-30 아시아 케미컬 인더스트리스 리미티드 루카파립 및 루카파립 염의 고체상 형태
CN109651377B (zh) * 2017-10-12 2020-10-20 成都海创药业有限公司 一种治疗癌症的化合物及其用途
MX2020004545A (es) 2017-11-03 2020-08-03 Sandoz Ag Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa.
US11220507B2 (en) 2017-12-15 2022-01-11 Advitech Advisory And Technologies Sa Process for the preparation of rucaparib and novel synthesis intermediates
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
PE20211305A1 (es) 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
WO2019207596A1 (en) 2018-04-25 2019-10-31 Mylan Laboratories Limited Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base
WO2019207498A1 (en) * 2018-04-25 2019-10-31 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of 8-fluoro-2-{4-[(methylamino)methyl] phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd] indol-6-one ((1s,4r)-7,7dimethyl-2-oxobicyclo [2.2.1] hept-1-yl) methanesulfonic acid salt (rucaparib camsylate) and the prerparation thereof
CN108743557A (zh) * 2018-06-27 2018-11-06 李莉 一种磷酸瑞卡帕布软胶囊及其制备方法
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN111217818A (zh) * 2018-11-27 2020-06-02 台耀化学股份有限公司 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法
CN111542527A (zh) 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
CN111004244A (zh) * 2019-12-27 2020-04-14 重庆市碚圣医药科技股份有限公司 一种瑞卡帕布樟脑磺酸盐的合成方法
EP4100125A1 (en) 2020-02-03 2022-12-14 Sandoz AG Polymorph of rucaparib mesylate
MX2022013258A (es) * 2020-04-24 2022-11-14 Astrazeneca Ab Formulaciones farmaceuticas.
BR112022021521A2 (pt) 2020-04-28 2023-01-24 Rhizen Pharmaceuticals Ag Compostos inovadores úteis como inibidores de poli(adp-ribose)polimerase (parp)
JP2023533982A (ja) 2020-07-10 2023-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｇａｓ４１阻害剤及びその使用方法
EP4182318A1 (en) 2020-07-14 2023-05-24 Assia Chemical Industries Ltd Solid state forms of rucaparib salts
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate
WO2023152754A1 (en) * 2022-02-08 2023-08-17 Sawant, Mohit Manikrao Crystalline form of rosuvastatin allyl ester

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489011A (en) 1983-05-16 1984-12-18 Merrell Dow Pharmaceuticals Inc. Hypoglycemic N-(2-substituted-3-dialkylamino-2-propenylidene)-N-alkylalkanaminium camsylate salts
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
DE4125292A1 (de) * 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT821671E (pt) 1995-04-20 2001-04-30 Pfizer Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69624081T2 (de) 1995-12-20 2003-06-12 Hoffmann La Roche Matrix-metalloprotease Inhibitoren
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
CN1230185A (zh) 1996-07-13 1999-09-29 葛兰素集团有限公司 双环芳杂环化合物用作蛋白质酪氨酸激酶的抑制剂
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
WO1998003516A1 (en) 1996-07-18 1998-01-29 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
EP0950059B1 (en) 1997-01-06 2004-08-04 Pfizer Inc. Cyclic sulfone derivatives
ES2202796T3 (es) 1997-02-03 2004-04-01 Pfizer Products Inc. Derivados de acidos arilsulfonilaminohidroxamicos.
EP0966438A1 (en) 1997-02-07 1999-12-29 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
JP3710489B2 (ja) 1997-02-11 2005-10-26 ファイザー・インク アリールスルホニルヒドロキサム酸誘導体
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
US5835420A (en) 1997-06-27 1998-11-10 Aplus Flash Technology, Inc. Node-precise voltage regulation for a MOS memory system
UA61963C2 (en) 1997-08-08 2003-12-15 Pfizer Prod Inc Aryloxysulfonylaminohydroxamic acid derivatives
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
CA2309690A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
EA005032B1 (ru) 1998-05-29 2004-10-28 Сьюджен, Инк. Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6114361A (en) 1998-11-05 2000-09-05 Pfizer Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
BR9916536A (pt) 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
CN100418967C (zh) 1999-01-11 2008-09-17 阿古龙制药公司 聚(adp-核糖)聚合酶的三环抑制剂
KR100452491B1 (ko) 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
KR20040011751A (ko) 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
CN1726208A (zh) 2002-12-19 2006-01-25 辉瑞产品公司 E－2－甲氧基－n－( 3－{4－[3－甲基－4－( 6－甲基－吡啶－3－基氧基)－苯基氨基]－喹唑啉－6－基}－烯丙基)－乙酰胺的配合物、其制备方法和用途
MXPA05010563A (es) * 2003-03-31 2005-11-23 Pfizer Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas.
DE602004025123D1 (en) 2003-07-25 2010-03-04 Pfizer Tricyclische parp-hemmer
BRPI0515567A (pt) 2004-09-22 2008-07-29 Pfizer combinações terapêuticas compreendendo inibidor de poli (adp-ribose) polimerase
CN101027306B (zh) 2004-09-22 2010-10-27 辉瑞有限公司 聚(adp-核糖)聚合酶抑制剂的制备方法
MX2007002461A (es) * 2004-09-22 2008-03-13 Pfizer Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona.
CN101384264B (zh) * 2004-09-22 2012-03-14 辉瑞大药厂 含有聚（adp-核糖）聚合酶抑制剂的治疗组合物
GB0502509D0 (en) 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
KR20140103356A (ko) * 2005-02-23 2014-08-26 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
RU2009103658A (ru) * 2006-07-05 2010-08-10 Тева Фармасьютикал Индастриес Лтд. (Il) Фармацевтические композиции мемантина
KR100843401B1 (ko) 2006-12-04 2008-07-04 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법
AU2007330478B2 (en) * 2006-12-06 2011-09-08 Conatus Pharmaceuticals, Inc. Crystalline forms of ( 3 S ) -3- [N- (N' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluorophenoxy) -4-oxopentanoic acid
WO2008114114A2 (en) * 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
EP2065385A1 (en) 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
US20110053997A1 (en) * 2007-12-05 2011-03-03 Alexander Beliaev Salts and Crystal Forms
KR20090060674A (ko) 2007-12-10 2009-06-15 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
ES2548131T3 (es) 2008-01-08 2015-10-14 Merck Sharp & Dohme Limited Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
SG173002A1 (en) 2009-01-17 2011-08-29 Boomerang Systems Inc Automated storage system and transport vehicle
EP3150610B1 (en) * 2010-02-12 2019-07-31 Pfizer Inc Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CN103930931A (zh) 2011-09-23 2014-07-16 金泰克斯公司 用于后视镜显示的系统和方法
MX2014007691A (es) 2011-12-26 2015-02-10 Wintech Polymer Ltd Gránulos de resina de polibutilentereftalato, y método de producción para dichos gránulos de resina de polibutilenterftalato .
US9384339B2 (en) 2012-01-13 2016-07-05 Telecommunication Systems, Inc. Authenticating cloud computing enabling secure services
US9697529B2 (en) 2012-03-13 2017-07-04 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
KR101984831B1 (ko) 2013-01-31 2019-05-31 삼성전자 주식회사 반도체 패키지 및 그 제조 방법
CN103309115B (zh) 2013-05-30 2016-03-23 京东方科技集团股份有限公司 彩色电泳显示面板及其制造方法、显示装置
US9501163B2 (en) 2014-05-06 2016-11-22 Symbol Technologies, Llc Apparatus and method for activating a trigger mechanism
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
CY1122218T1 (el) 2020-11-25
IL220921B (en) 2020-03-31
DK2534153T3 (en) 2017-01-09
US20150238504A1 (en) 2015-08-27
NO2018039I1 (no) 2018-11-15
HUS1800046I1 (hu) 2018-12-28
EP3150610A1 (en) 2017-04-05
JP6013551B2 (ja) 2016-10-25
SG182533A1 (en) 2012-08-30
HUE047248T2 (hu) 2020-04-28
AU2011213944A1 (en) 2012-08-09
BR112012019050A2 (pt) 2016-09-13
LT3150610T (lt) 2019-11-11
JP6371350B2 (ja) 2018-08-08
NL300958I2 (nl) 2018-12-19
JP2011168587A (ja) 2011-09-01
US20120302550A1 (en) 2012-11-29
US20180092925A1 (en) 2018-04-05
LT2534153T (lt) 2016-12-12
PL3150610T3 (pl) 2020-02-28
JP2020050671A (ja) 2020-04-02
SI2534153T1 (sl) 2017-01-31
LUC00093I2 (no) 2019-12-24
US20140243318A1 (en) 2014-08-28
SMT201600462B (it) 2017-03-08
WO2011098971A1 (en) 2011-08-18
LTC2534153I2 (lt) 2021-03-10
EP3597651A1 (en) 2020-01-22
JP2018199679A (ja) 2018-12-20
CA3024216A1 (en) 2011-08-18
HUE030969T2 (en) 2017-06-28
JP6640931B2 (ja) 2020-02-05
SG10201406805RA (en) 2014-11-27
PT2534153T (pt) 2016-12-27
SI3150610T1 (sl) 2019-12-31
EP3150610B1 (en) 2019-07-31
AR109356A2 (es) 2018-11-21
PL2534153T3 (pl) 2017-08-31
CY2018031I1 (el) 2019-11-27
AR080164A1 (es) 2012-03-21
EP2534153A1 (en) 2012-12-19
TW201144316A (en) 2011-12-16
US10278974B2 (en) 2019-05-07
AU2011213944B2 (en) 2014-10-02
TWI545123B (zh) 2016-08-11
ES2753748T3 (es) 2020-04-14
EP4166558A1 (en) 2023-04-19
CA2787881A1 (en) 2011-08-18
KR20190026043A (ko) 2019-03-12
JP2016216507A (ja) 2016-12-22
US9861638B2 (en) 2018-01-09
JP5745283B2 (ja) 2015-07-08
KR102108226B1 (ko) 2020-05-08
CA2787881C (en) 2019-01-08
DK3150610T3 (da) 2019-11-04
CY1118319T1 (el) 2017-06-28
LTPA2018517I1 (lt) 2018-12-10
CY2018031I2 (el) 2019-11-27
MX343383B (es) 2016-11-03
RU2012138892A (ru) 2014-03-20
CA3024216C (en) 2021-03-30
US8754072B2 (en) 2014-06-17
CN102884066B (zh) 2015-01-07
ES2607806T3 (es) 2017-04-04
LUC00093I1 (no) 2018-11-15
PT3150610T (pt) 2019-11-11
NZ601445A (en) 2014-08-29
CN104876937A (zh) 2015-09-02
JP2015131858A (ja) 2015-07-23
RU2570198C2 (ru) 2015-12-10
RS59494B1 (sr) 2019-12-31
HRP20191944T1 (hr) 2020-01-24
CN104876937B (zh) 2017-07-28
JP2021107460A (ja) 2021-07-29
CN102884066A (zh) 2013-01-16
KR20120127495A (ko) 2012-11-21
RS55487B1 (sr) 2017-04-28
US20200000821A1 (en) 2020-01-02
MX2012008911A (es) 2012-08-15
US9045487B2 (en) 2015-06-02
HRP20161742T1 (hr) 2017-02-24
BR112012019050A8 (pt) 2017-12-26
EP2534153B1 (en) 2016-09-21

Similar Documents

Publication Publication Date Title
HK1176617A1 (zh) -{ }- -氟- -{ 甲氨基 甲基 苯基}- -四氫- -氮雜並 吲哚- -酮的鹽和多晶型物
EP2205611A4 (en) PROCESS FOR THE PRODUCTION OF PRASUGREL AND SALTS AND POLYMERS THEREOF
IL216609A0 (en) Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
IL215251A0 (en) Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
HK1163450A1 (zh) 氨基酯類衍生物及其鹽和使用方法
IL223725B (en) Formulations of rifaximin and uses thereof
ZA201106894B (en) Method of folding absorbent article
HK1176556A1 (en) N-9-substituted purine compounds, compositions and methods of use n-9-
AP3222A (en) Germination-stimulant carbamate derivatives and process for preparation thereof
IL248077A0 (en) Formulations, salts and polymers of transnorsertraline and their uses
ZA201308268B (en) Herbicidal composition comprising pinoxaden and fluroxypyrester, and methods of use thereof
EP2269994A4 (en) POLYMORPHES OF 4-ANILINOCHINAZOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USES
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
EP2701504A4 (en) Sulindac derivatives, their use and preparation
EP2503891A4 (en) PYRIMIDINE ETHER DERIVATIVES AND METHOD OF USE THEREOF
GB2488494B (en) Solution, use and method of preparation thereof
PL2477990T3 (pl) Pochodne 5-fenylopirazolopirydyny, ich wytwarzanie oraz ich zastosowanie terapeutyczne
EP2581375A4 (en) IMPROVED METHODS FOR THE PREPARATION OF QUINOXALINE DERIVATIVES
EP2467375A4 (en) FORMS OF DEXLANDSOPRAZOLE AND METHOD OF MANUFACTURING THEREOF
EP2699560A4 (en) 5-CARBAMOYL-ADAMANTAN-2-YL AMID DERIVATIVES, PHARMACEUTICALLY ALLOWED SALTS AND METHOD FOR THE PRODUCTION THEREOF
EP2507222A4 (en) SALACINOL AND PONCORANOL HOMOLOGOUS, DERIVATIVES THEREOF AND METHOD FOR THEIR SYNTHESIS